Trials / Completed
CompletedNCT02256852
Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer
Open Label,Single Arm,Exploratory Study to Evaluate the Safety,Tolerability,Compliance and MOA,of QBKPN SSI in Subjects With 2 or More Second Primary Pre-invasive/Invasive Adenocarcinoma Following Surgical Resection of Stage I NSCLC
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Qu Biologics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, compliance and mechanism of action of study drug (QBKPN SSI) in subjects with two or more second primary pre-invasive or invasive adenocarcinoma following surgical section of Stage 1 NSCLC.
Detailed description
Please refer to summary above.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | QBKPN SSI | QBKPN SSI is administered subcutaneously for 12 weeks |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2015-11-01
- Completion
- 2015-11-01
- First posted
- 2014-10-06
- Last updated
- 2016-02-22
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02256852. Inclusion in this directory is not an endorsement.